Hospital das Clínicas de Ribeirão Preto
Hospital das Clínicas de Ribeirão Preto
Campus Universitário S/N, Bloco G Subsolo II, Monte Alegre, Ribeirão Preto, Sao Paulo
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Camila Donadel
Raphael Liberatore, Jr.
Ligia Moreira Freitas
Rogerio Parra
Irai S Oliveira
Sabrina Ando
Maristella dos Reis
Open studies
Lung cancer
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer - Hospital das Clínicas de Ribeirão PretoSee more
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) - KANDLELIT-007 - Merck Sharp & Dohme LLCSee more
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer - DESTINY-Lung06 - Daiichi SankyoSee more
Crohn's disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) - MK-7240-008 - Merck Sharp & Dohme LLCSee more
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) - MK-7240-008 - Merck Sharp & Dohme LLCSee more
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease - AMAY - Eli Lilly and CompanySee more
Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL - AmgenSee more
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) - BRUIN-CLL-314 - Loxo Oncology, Inc.See more
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer - DESTINY-Breast15 - Daiichi SankyoSee more
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more
Gastroesophageal cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
Non-Hodgkin Lymphoma
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) - BRUIN-CLL-314 - Loxo Oncology, Inc.See more
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) - BRUIN-CLL-314 - Loxo Oncology, Inc.See more
Hidradenitis suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Step-Up HS - AbbVieSee more
Prostate cancer
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) - MK-2400-01A/IDeate-Prostate02 - Merck Sharp & Dohme LLCSee more
Gastric cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer - Destiny-Gastric05 - Daiichi SankyoSee more
Sleep disorders
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke - ATACS - Hospital das Clínicas de Ribeirão PretoSee more
Stroke
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke - ATACS - Hospital das Clínicas de Ribeirão PretoSee more
Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis - Start Up - AbbVieSee more
